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Iron is an essential nutrient required for numerous cellular process and its homeostasis is a tightly regulated. In plasma, iron exists
bound to transferrin. Upon transferrin binding to its cognate receptor, it is internalized through clathrin-mediated endocytic process.
Ferristatin is a small molecule inhibitor previously shown to block iron assimilation from transferrin. Now, Horonchik and Wessling-
Resnick demonstrate that ferristatin induces internalization and degradation of transferrin receptors by a lipid-raft-mediated path-
way. Internalization promoted by ferristatin is independent of clathrin and dynamin and is blocked by the cholesterol-depleting
agents fillipin and nystatin. The degradation of transferrin receptors by this novel pathway is sensitive to both proteosomal and
lysosomal inhibitors and ultimately accounts for ferristatin’s ability to block transferrin-mediated iron uptake.
Glycosphingilipids/Natural Killer T-Cells Face Off
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Natural killer T (NKT) cells have been shown to recognize glyco-
sphingolipids (GSLs) from sphingomonas bacteria. The antigens
previously tested contain a monosaccharide and a C18:0 sphingo-
sine lipid. These bacteria, however, also have oligosaccharides
containing GSLs and GSLs with different sphingosines, including
a C21:0 sphingosine with a cyclopropyl ring (C21cycl). Kinjo et al.
studied the stimulation of NKT cells with synthetic GSLs containing
natural tetrasaccharide sugars or the C21cyclo sphingosine. The
results indicate variability in the antigenic potency of different
sphingomonas GSLs, with the C21cyclo sphingosine having
intermediate potency, and the oligosaccharide-containing anti-
gens exhibiting limited or no stimulatory capacity.
Targerting Prostate-Specific Antigen
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Prostate cancer cells exclusively produce high levels of prostate-specific antigen (PSA) and, for this reason, PSA is the biomarker
used to detect prostate cancer and monitor therapeutic response. Functionally, PSA is a serine protease. Emerging evidence
suggests that PSA’s proteolytic activity plays a role in the pathobiology of prostate cancer. To better understand this role and to
potentially develop targeted imaging and therapeutic agents, LeBeau et al. have used an iterative approach to identify potent and
selective peptidyl boronic acid PSA inhibitors. The application of these peptidyl inhibitors towards the therapy and imaging of human
prostate cancer is currently under evaluation.
OX40 Receptor-Activating Aptamer
PAGE 675
Therapeutic manipulation of immune responses for the treatment of diseases including
cancer has become an important focus of biomedical research. Many receptors are
activated bymultimerization on the cell surface. Molecular scaffolds have been utilized
to assemble multiple receptor-binding peptide ligands to induce receptor multimeriza-
tion and activation. Dollins et al. demonstrate that a flexible molecular scaffold can
be used to convert an RNA ligand (aptamer) that recognizes OX40, a member of the
tumor necrosis factor receptor superfamily, into a receptor agonist. Such OX40 recep-
tor-activating aptamers can induce receptor function and enhance the potency of
tumor vaccines in mice. (Figure adopted from Dollins et al.)
Protein Kinase CK2 – get the POM-POMs
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Protein kinase CK2 is disregulated in number of cancers and is now considered to be a highly relevant pathophysiological target, thus
creating a need for the identification of the appropriate chemical inhibitors. Prudent et al. present the identification and the charac-
terization of the unique class of non-ATP-competitive CK2 inhibitors, polyoxometalates (POMs). POMs are inorganic complexes
formed between early transition metal ions (VV, MoVI, or WVI) and oxo ligands. As inhibitors, POMs exhibit a remarkable activity
and a striking specificity for CK2, targeting a domain outside the ATP- and peptide substrate-binding sites. Thus, these compounds
represent nonclassical kinase inhibitors interacting with CK2 in a unique way.Chemistry & Biology 15, July 21, 2008 ª2008 Elsevier Ltd All rights reserved ix
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Azinomycin B is a complex natural product with potent antitumor activity. To produce the highly diverse functionalities present in its
final structure, azinomycin B biosynthetic machinery had to evolve different strategies, including (1) incorporation of unusual building
blocks into the nonribosomal peptide synthetase (NRPS) assembly line, (2) NRPS on line modification, (3) reductive release of the
assembled intermediate as an aldehyde, and (4) NRPS-post modifications. Zhao et al. now characterize AziB and demonstrate
that AziB is a 5-methyl-naphthoic acid (NPA) synthase. AziB is a new member to bacterial iterative type I polyketide synthases
(PKSs) and shows the fourth selective reductive pattern in aromatic polyketide biosynthesis governed by this family.
Bulky Lesion Not a Problem
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The challenge for DNA glycosylases, enzymes involved in the base excision repair
pathway, such Fpg and hOgg1, is to identify and remove one lesion among millions
of undamaged bases by not only identifying small lesions that didn’t cause large
disruptions of local DNA structures, but also by accommodating and processing bulky
lesions using the same active site. Combining chemical synthesis of derivatized DNA
molecules, designed tomimic small and large lesions,with comparative structural anal-
ysis of Fpgbound to damagedDNA,Coste et al. established themolecular basis for for-
mation of an unproductive but stable complex between Fpg and the bulky DNA lesion.
The authors suggest that formation of this unproductive complex inhibits DNA repair
processes, thus explaining the long persistence of these lesions observed in vivo.
CFTR Takes Double Punch
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Secretory diarrheas such as cholera and Traveler’s diarrhea are major health problems
in developing countries. The CFTR chloride channel provides the main pathway for fluid secretion into the intestine in secretory
diarrheas. Sonawane et al. synthesized a series of polyethylene glycol-conjugated CFTR inhibitors that block CFTR by occluding
its external pore. A substantially higher potency of divalent versus monovalent conjugates was found, which appears to result
from a cooperative binding mechanism. Good potency, chemical stability, and membrane impermeability of the compounds
developed in this study make them highly attractive candidates for further preclinical development.
Indole Prenyltransferases Now in the Role of Aminopeptidase
PAGE 729
Prenyltransferases catalyze the transfer of allylic prenyl groups to acceptor
molecules. Kremer and Li now show that four recently identified indole pre-
nyltransferases form Aspergillus fumigatus AF293 also exhibit tryptophan
aminopeptidase activities. This unique catalytic promiscuity of prenyltrans-
ferases is readily distinguishable from prenyltransferase reaction. For exam-
ple, aminopeptidase activities could be inhibited by addition of EDTA, in con-
trast to the prenyltransfer reactions catalyzed by the same enzymes, which
are independent of the metal ions’ presence. The results described here pro-
vide further supports for the hypothesis that the indole prenyltransferases
from fungi have evolved directly from a common ancestor. (Figure credits:
Kremer and Li)
Macrolides Inhibit Glycosidase
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Macrolides are a large class of clinically relevant drugs, mostly known for their antibiotic activity due to their ability to affect bacterial
protein biosynthesis through interaction with ribosome. Sadeghi-Khomami et al. now report that macrolides act as competitive
inhibitors of glycosidases by binding directly to the active site. The work highlights the value of saturation transfer difference nuclear
magnetic resonance (STD-NMR) spectroscopy that enabled the authors tomonitor binding of substrates to inactive enzyme variants,
providing insight into the enzyme active site structure and recognition of nonphysiological substrates and inhibitors. Whether there is
any clinical significance to the inhibition of glycosidases by macrolide antibiotics remains to be determined.x Chemistry & Biology 15, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
